Mitochondrial Dysfunction in the Transition from NASH to HCC

被引:64
|
作者
Leveille, Melissa [1 ,2 ]
Estall, Jennifer L. [1 ,2 ,3 ]
机构
[1] IRCM, Quebec City, PQ H2W 1R7, Canada
[2] Univ Montreal, Fac Med, Quebec City, PQ H3G 2M1, Canada
[3] McGill Univ, Div Expt Med, Quebec City, PQ H4A 3J1, Canada
关键词
mitochondria; metabolism; liver; NAFLD; NASH; HCC; NONALCOHOLIC FATTY LIVER; PROLIFERATOR-ACTIVATED RECEPTOR; GAMMA-COACTIVATOR; 1-ALPHA; UNFOLDED PROTEIN RESPONSE; PLACEBO-CONTROLLED TRIAL; ONE-CARBON METABOLISM; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; VITAMIN-E; ENDOPLASMIC-RETICULUM;
D O I
10.3390/metabo9100233
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The liver constantly adapts to meet energy requirements of the whole body. Despite its remarkable adaptative capacity, prolonged exposure of liver cells to harmful environmental cues (such as diets rich in fat, sugar, and cholesterol) results in the development of chronic liver diseases (including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)) that can progress to hepatocellular carcinoma (HCC). The pathogenesis of these diseases is extremely complex, multifactorial, and poorly understood. Emerging evidence suggests that mitochondrial dysfunction or maladaptation contributes to detrimental effects on hepatocyte bioenergetics, reactive oxygen species (ROS) homeostasis, endoplasmic reticulum (ER) stress, inflammation, and cell death leading to NASH and HCC. The present review highlights the potential contribution of altered mitochondria function to NASH-related HCC and discusses how agents targeting this organelle could provide interesting treatment strategies for these diseases.
引用
收藏
页数:28
相关论文
共 50 条
  • [21] Molecular landscape of NASH-HCC
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 : 456 - 456
  • [22] Mitochondrial dysfunction and the AKI-to-CKD transition
    Jiang, Mingzhu
    Bai, Mi
    Lei, Juan
    Xie, Yifan
    Xu, Shuang
    Jia, Zhanjun
    Zhang, Aihua
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 319 (06) : F1105 - F1116
  • [23] PPARs and Mitochondrial Metabolism: From NAFLD to HCC
    Mello, Tommaso
    Materozzi, Maria
    Galli, Andrea
    PPAR RESEARCH, 2016, 2016
  • [24] Immunotherapy for HCC: limitations in patients with NASH
    Agarwal, Parul D.
    Lucey, Michael R.
    Said, Adnan
    Kratz, Jeremy
    ANNALS OF HEPATOLOGY, 2023, 28 (02)
  • [25] The paradox of immunotherapy in NASH-HCC
    Peng, Yao
    Wong, Chi Chun
    Yu, Jun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [26] Intermittent fasting for NASH and HCC in mice
    Hindson, Jordan
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (07) : 461 - 461
  • [27] The paradox of immunotherapy in NASH-HCC
    Yao Peng
    Chi Chun Wong
    Jun Yu
    Signal Transduction and Targeted Therapy, 6
  • [28] The Role of Oxidative Stress in NAFLD-NASH-HCC Transition-Focus on NADPH Oxidases
    Gabbia, Daniela
    Cannella, Luana
    De Martin, Sara
    BIOMEDICINES, 2021, 9 (06)
  • [29] Mitochondrial dysfunction in lymphocytes from old mice: Enhanced activation of the permeability transition
    Rottenberg, H
    Wu, SL
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 240 (01) : 68 - 74
  • [30] THE GENETIC BACKGROUND SHAPES DISEASE SUSCEPTIBILITY AND REVEALS A SPECIFIC ROLE FOR MITOCHONDRIAL DYSFUNCTION IN THE PROGRESSION FROM NAFLD TO NASH
    Benegiamo, Giorgia
    Von Alvensleben, Giacomo
    Liu, Yasmine
    Rodriguez-Lopez, Sandra
    Bachmann, Alexis
    Morel, Jean-David
    Broeckx, Ellen
    Jing Ying Ma
    Carreira, Vinicius
    Youssef, Sameh A.
    Azhar, Nabil
    Reilly, Dermot
    D'Aquino, Katharine
    Mullican, Shannon
    Bou-Sleiman, Maroun
    Auwerx, Johan
    HEPATOLOGY, 2022, 76 : S633 - S634